Regulator of gene expression responsible for the progression of breast cancer

by Bill Hathaway
Gene regulator critical for breast cancer metastasis to the lung is identified
Credit: Shutterstock

Yale Cancer Center researchers have identified a regulator of gene expression that is responsible for the progression of breast cancer and its metastasis to the lung. The study appears online in Cell Reports.

In women, breast cancer is the most common cancer, and the second leading cause of cancer-related death. When it metastasizes, it does so primarily to the lung, brain, and bone. Only limited treatment options are available, and scientists are working to identify and test new drug targets for the development of effective therapies.

Recent studies suggest that abnormal gene expression contributes significantly to tumor formation and progression. But the regulators of such changes in metastasis are poorly understood.

The Yale researchers analyzed datasets of human breast tumors, as well as those of cancer cells, and found that overexpression of the enzyme RBP2 is critical for to the lung. Loss of RBP2, they also found, suppressed in mouse models.

The authors say their evidence suggests that RBP2 regulates a critical epigenetic switch that sets the stage for . They say the enzyme offers a novel target for development of therapies designed to inhibit and metastasis.

"Metastasis is the major cause of breast cancer-related death," said senior author Qin Yan, assistant professor of pathology at Yale School of Medicine. "Our study provides the first evidence, in genetically engineered mice, that a new class of enzymes could be targeted to suppress tumor metastasis."

add to favorites email to friend print save as pdf

Related Stories

New signaling pathway linked to breast cancer metastasis

Apr 02, 2012

Lymph nodes help to fight off infections by producing immune cells and filtering foreign materials from the body, such as bacteria or cancer cells. Thus, one of the first places that cancer cells are found when they leave ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

2 minutes ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

9 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.